StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Moderna (MRNA) downgraded as HSBC skeptical on medium term INT Phase 3 data readouts
February 26, 2024 9:33 AM
HSBC analysts cut Moderna (NASDAQ: MRNA) to Reduce from Hold in a note Monday, raising the price target to $86 ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst PT Change
Downgrades
Hot List
Next Articles
Midday movers: Alcoa, Moderna fall; Micron, Coinbase rise
February 26, 2024 8:00 AM
HSBC Downgrades Moderna (MRNA) to Reduce, 'INT marches on but RSV alerts'
February 26, 2024 2:48 AM
Form S-8 Moderna, Inc.
February 23, 2024 4:24 PM
Form 10-K Moderna, Inc. For: Dec 31
February 23, 2024 4:06 PM
Form 4 Moderna, Inc. For: Feb 22 Filed by: Hoge Stephen
February 23, 2024 4:05 PM
Moderna's CMV trial offers further upside - UBS
February 23, 2024 9:39 AM
Moderna (MRNA) PT Lowered to $89 at Morgan Stanley
February 23, 2024 8:54 AM
Moderna (MRNA) PT Raised to $91 at Canaccord Genuity
February 23, 2024 7:13 AM
